Recce Pharmaceuticals Ltd (ASX:RCE)

Market Cap	115.30M +6.3%
Revenue (ttm)	974.56K -89.8%
Net Income	-30.25M
EPS	-0.11
Shares Out	299.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,051
Open	0.3850
Previous Close	0.3850
Day's Range	0.3750 - 0.3850
52-Week Range	0.3470 - 0.7300
Beta	0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. The company’s lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infect...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RCE

Financial Performance

In fiscal year 2025, Recce Pharmaceuticals's revenue was 7.51 million, an increase of 49.33% compared to the previous year's 5.03 million. Losses were -21.43 million, 21.3% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 11, 2026

Data Sources Report a data error